UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 26

Sortiert nach

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

Nature reviews. Drug discovery, 2010-11, Vol.9 (11), p.883-897

2010

Link zum Volltext

Verfügbarkeit prüfen

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

The New England journal of medicine, 2010-02, Vol.362 (5), p.387-401

2010

Link zum Volltext

Verfügbarkeit prüfen

Erratum: Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

Nature reviews. Drug discovery, 2010-12, Vol.9 (12), p.955-955

2010

Link zum Volltext

Verfügbarkeit prüfen

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

Nature reviews. Drug discovery, 2010-12, Vol.9 (12), p.955-955

2010

Link zum Volltext

Verfügbarkeit prüfen

Pimecrolimus Identifies a Common Genomic Anti-inflammatory Profile, is Clinically Highly Effective in Psoriasis and is Well Tolerated

Journal of investigative dermatology, 2002-10, Vol.119 (4), p.876-887

2002

Link zum Volltext

Verfügbarkeit prüfen

Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis

Archives of neurology (Chicago), 2012-10, Vol.69 (10), p.1259

2012

Link zum Volltext

Verfügbarkeit prüfen

Safety of metronidazole in pregnancy: A meta-analysis

American journal of obstetrics and gynecology, 1995-02, Vol.172 (2), p.525-529

1995

Link zum Volltext

Verfügbarkeit prüfen

Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases

Expert opinion on emerging drugs, 2003-05, Vol.8 (1), p.47-62

2003

Link zum Volltext

Verfügbarkeit prüfen

Clinical pharmacokinetics of sedatives in neonates

Clinical pharmacokinetics, 1996-12, Vol.31 (6), p.423-443

1996

Link zum Volltext

Verfügbarkeit prüfen

Low Systemic Absorption and Good Tolerability of Pimecrolimus, Administered as 1% Cream (Elidel®) in Infants with Atopic Dermatitis - A Multicenter, 3-Week, Open-Label Study

Pediatric dermatology, 2005-09, Vol.22 (5), p.465-471

2005

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetics of midazolam in neonates

Clinical pharmacology and therapeutics, 1994-12, Vol.56 (6), p.615-625

1994

Link zum Volltext

Verfügbarkeit prüfen

Is saliva suitable for therapeutic monitoring of anticonvulsants in children : An evaluation in the routine clinical setting

Therapeutic drug monitoring, 1997-12, Vol.19 (6), p.637-642

1997

Link zum Volltext

Verfügbarkeit prüfen

Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (Elidel®) for up to 1 year

The Journal of dermatological treatment, 2007, Vol.18 (1), p.19-22

2007

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of pimecrolimus, a novel nonsteroid anti-inflammatory drug, after single and multiple Oral administration

Clinical pharmacokinetics, 2003-01, Vol.42 (14), p.1305-1314

2003

Link zum Volltext

Verfügbarkeit prüfen

Saliva versus blood sampling for therapeutic drug monitoring in children : patient and parental preferences and an economic analysis

Therapeutic drug monitoring, 1994-10, Vol.16 (5), p.437-443

1994

Link zum Volltext

Verfügbarkeit prüfen

Use of Human Skin Equivalent Apligraf for in Vitro Assessment of Cumulative Skin Irritation Potential of Topical Products

Toxicology and applied pharmacology, 2000-04, Vol.164 (1), p.38-45

2000

Link zum Volltext

Verfügbarkeit prüfen

Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis

Dermatology (Basel), 2002, Vol.204 (1), p.63

2002

Link zum Volltext

Verfügbarkeit prüfen

Clinical relevance of therapeutic drug monitoring of Digoxin and gentamicin in the saliva of children

Therapeutic drug monitoring, 1998-06, Vol.20 (3), p.253-256

1998

Link zum Volltext

Verfügbarkeit prüfen

Sparse-Sampling Optimal Designs in Pharmacokinetics and Toxicokinetics

Therapeutic innovation & regulatory science, 1995, Vol.29 (3), p.997-1019

1995

Link zum Volltext

Verfügbarkeit prüfen

Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulo-interstitial lesions after renal injury

The Journal of clinical investigation, 2000-07, Vol.106 (2), p.225-234

2000

Link zum Volltext

Verfügbarkeit prüfen

Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: Implications for immunotherapy

International journal of cancer, 2012-08, Vol.131 (4), p.E449-E462

2012

Link zum Volltext

Verfügbarkeit prüfen

Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of V[gamma]9V[delta]2 T cells impaired by the prostaglandin E2 immunosuppressive factor: Implications for immunotherapy

International journal of cancer, 2012-08, Vol.131 (4), p.E449-E462

2012

Link zum Volltext

Verfügbarkeit prüfen

Proliferation and Remodeling of the Peritubular Microcirculation after Nephron Reduction : Association with the Progression of Renal Lesions

The American journal of pathology, 2001-08, Vol.159 (2), p.547-560

2001

Link zum Volltext

Verfügbarkeit prüfen

Proliferation and Remodeling of the Peritubular Microcirculation after Nephron Reduction

The American journal of pathology, 2001-08, Vol.159 (2), p.547-560

2001

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(25)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(18)
Life Sciences & Biomedicine
(17)
Science & Technology
(17)
Biological And Medical Sciences
(15)
Medical Sciences
(15)
Female
(12)
Male
(11)
Pharmacology & Pharmacy
(9)
Pharmacology. Drug Treatments
(9)
Adult
(8)
Middle Aged
(6)
Double-Blind Method
(5)
Tacrolimus - Analogs & Derivatives
(5)
Administration, Oral
(4)
Adolescent
(4)
Animals
(4)
Dose-Response Relationship, Drug
(4)
Infant
(4)
Multiple Sclerosis
(4)
Tacrolimus - Administration & Dosage
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

Erratum: Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

Pimecrolimus Identifies a Common Genomic Anti-inflammatory Profile, is Clinically Highly Effective in Psoriasis and is Well Tolerated

Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis

Safety of metronidazole in pregnancy: A meta-analysis

Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases

Clinical pharmacokinetics of sedatives in neonates

Low Systemic Absorption and Good Tolerability of Pimecrolimus, Administered as 1% Cream (Elidel®) in Infants with Atopic Dermatitis - A Multicenter, 3-Week, Open-Label Study

Population pharmacokinetics of midazolam in neonates

Is saliva suitable for therapeutic monitoring of anticonvulsants in children : An evaluation in the routine clinical setting

Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (Elidel®) for up to 1 year

Pharmacokinetics of pimecrolimus, a novel nonsteroid anti-inflammatory drug, after single and multiple Oral administration

Saliva versus blood sampling for therapeutic drug monitoring in children : patient and parental preferences and an economic analysis

Use of Human Skin Equivalent Apligraf for in Vitro Assessment of Cumulative Skin Irritation Potential of Topical Products

Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis

Clinical relevance of therapeutic drug monitoring of Digoxin and gentamicin in the saliva of children

Sparse-Sampling Optimal Designs in Pharmacokinetics and Toxicokinetics

Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulo-interstitial lesions after renal injury

Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: Implications for immunotherapy

Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of V[gamma]9V[delta]2 T cells impaired by the prostaglandin E2 immunosuppressive factor: Implications for immunotherapy

Proliferation and Remodeling of the Peritubular Microcirculation after Nephron Reduction : Association with the Progression of Renal Lesions

Les historiens croient-ils aux mythes ?

Proliferation and Remodeling of the Peritubular Microcirculation after Nephron Reduction

Suchergebnisse filtern